160,041 Shares in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Bought by XTX Topco Ltd

Key Points

• XTX Topco Ltd has made a new investment of approximately $2.46 million in Teva Pharmaceutical Industries Ltd., purchasing 160,041 shares during the first quarter.
• Teva reported a positive EPS of $0.52 for its latest quarter, exceeding analysts' expectations, with revenue of $3.89 billion.
• Several analysts have recently upgraded Teva's stock rating, with price targets rising significantly; Bank of America raised its price objective from $20.00 to $22.00, while JPMorgan set a new target of $23.00.

XTX Topco Ltd bought a new stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 160,041 shares of the company's stock, valued at approximately $2,460,000.

A number of other hedge funds also recently added to or reduced their stakes in TEVA. Oarsman Capital Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at approximately $29,000. Golden State Wealth Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $39,000. Marshall & Sterling Wealth Advisors Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at approximately $44,000. Compagnie Lombard Odier SCmA acquired a new stake in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $54,000. Finally, Banque Cantonale Vaudoise acquired a new stake in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $74,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Teva Pharmaceutical Industries

In other news, EVP Matthew Shields sold 6,206 shares of the firm's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the transaction, the executive vice president owned 9,989 shares of the company's stock, valued at approximately $170,012.78. This trade represents a 38.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.49% of the company's stock.

Teva Pharmaceutical Industries Trading Down 0.5%

Shares of TEVA stock traded down $0.07 on Friday, reaching $15.38. 14,134,278 shares of the stock were exchanged, compared to its average volume of 12,253,167. The stock has a market cap of $17.64 billion, a P/E ratio of -96.13, a price-to-earnings-growth ratio of 0.99 and a beta of 0.60. The company has a quick ratio of 0.74, a current ratio of 1.03 and a debt-to-equity ratio of 2.59. The firm has a 50 day moving average of $16.89 and a two-hundred day moving average of $16.67. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 47.68%. The business had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. During the same quarter last year, the firm posted $0.61 EPS. The business's revenue for the quarter was up .3% compared to the same quarter last year. On average, research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on TEVA. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and increased their price target for the company from $21.00 to $23.00 in a research report on Monday, May 12th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Truist Financial assumed coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price on the stock. UBS Group decreased their target price on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. Finally, Bank of America raised their target price on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $24.71.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.